Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: oldcoach19 who wrote (1782)	3/28/2016 2:27:27 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

OC, pretty sure it is sales (and not RTD or something else). I think I got that from Eman after one of his conference conversations with Pascoe...but Eman is the best source. And, of course, we have no idea on level of sales that would be the trigger.

To: oldcoach19 who wrote (1782)	3/28/2016 2:50:07 PM
From: mokelumne river	Respond to of 2026

On the subject of Pascoe, I do give him credit for negotiating the return of US rights to Vitaros, an achievement that I thought would never happen. That is now our best bet for recovery. I wonder who will be on the chopping block. I don't see much need for Neil Morton as the company should not be interested in business development beyond licensing Vitaros in Asia and perhaps negotiating with Allergan/Pfizer on US-Vitaros. Dr. Barbara Troupin might be helpful in putting together the application to the FDA for Vitaros approval. I don't know what Brian Dorsey does.